NCT06825702Phase 2Recruiting

Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

Study sponsor: Kiora Pharmaceuticals, Inc. · KPRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-11Estimated
Enrollment · participants28Estimated
Source updated2026-09-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview